China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
Rang in Aktien
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Aktienkurs
$3.74
Marktkapitalisierung
$6.23B
Veränderung (1 Tag)
-2.11%
Veränderung (1 Jahr)
-8.54%
Land
CN
Handel China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Kategorie
Healthcare
Gewinn für China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Gewinn im Jun 2026 TTM: $714.70M
Laut den aktuellen Finanzberichten von China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. betragen die aktuellen Gewinne des Unternehmens $714.70M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $629.34M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $530.39M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. von 2001 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $714.70M | 2.80% |
| 2025 | $695.23M | 10.47% |
| 2024 | $629.34M | 18.65% |
| 2023 | $530.39M | 37.94% |
| 2022 | $384.52M | 21.98% |
| 2020 | $315.25M | -14.08% |
| 2019 | $366.92M | 46.83% |
| 2018 | $249.89M | 7.08% |
| 2017 | $233.36M | 11.49% |
| 2016 | $209.31M | -11.11% |
| 2015 | $235.46M | 15.78% |
| 2014 | $203.36M | -9.34% |
| 2013 | $224.32M | 8.45% |
| 2012 | $206.84M | 37.53% |
| 2011 | $150.40M | -4.00% |
| 2010 | $156.66M | 18.25% |
| 2009 | $132.48M | 39.94% |
| 2008 | $94.67M | 79.81% |
| 2007 | $52.65M | 60.01% |
| 2006 | $32.90M | 52.20% |
| 2005 | $21.62M | -126.33% |
| 2004 | $-82.11M | -349.03% |
| 2003 | $32.97M | 44.24% |
| 2002 | $22.86M | 11.09% |
| 2001 | $20.58M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $3.62B | 406.21% |
DE
|
|
| $3.40B | 376.42% |
DE
|
|
| $1.72B | 141.17% |
JP
|
|
| $930.30M | 30.17% |
CH
|
|
| $1.69B | 136.83% |
IN
|
